Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 9,813 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Advanced Clear all

Conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
Interventions: bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin; Biological · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 2
States / cities: San Francisco, California • Vallejo, California

Conditions: Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female
Interventions: Pazopanib, Paclitaxel, Carboplatin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions: EndoTAG-1, Gemcitabine; Drug
Lead sponsor: SynCore Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 16
States / cities: Corona, California • Atlanta, Georgia • Columbus, Georgia + 12 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, pH Low Insertion Peptide-exatecan Conjugate CBX-12; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: filgrastim, therapeutic autologous lymphocytes, cyclophosphamide, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, HER2-negative Breast Cancer
Interventions: Paclitaxel, Eribulin, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 18
States / cities: Denver, Colorado • Miami Beach, Florida • Albany, Georgia + 13 more

Conditions: Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Interventions: Enfortumab vedotin, Pembrolizumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer
Interventions: ADCT-301, Pembrolizumab; Drug · Biological
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more

Conditions: Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor
Interventions: IOV-5001; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2044
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumor Malignancies
Interventions: ASA404, DMXAA, DXAA; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 2
States / cities: Houston, Texas • Madison, Wisconsin

Conditions: Lung Cancer
Interventions: Paclitaxel, Pemetrexed, Bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Carcinoma, Renal Cell
Interventions: ABT-510/Thrombospondin-1 mimetic; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 17
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 12 more

Conditions: Advanced Solid Cancers, Metastatic Cancer
Interventions: Cdc7-inhibitor; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Breast Cancer
Interventions: GDC-0810, LHRH Agonist, Palbociclib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 8
States / cities: San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
Interventions: IDE034; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more

Conditions: Advanced Solid Tumors
Interventions: LAG525, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 6
States / cities: New York, New York • Durham, North Carolina • Houston, Texas + 2 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: carboplatin, oglufanide disodium, paclitaxel, conventional surgery; Drug · Procedure
Lead sponsor: Cytran; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 19
States / cities: Glendale, California • Los Gatos, California • Stanford, California + 15 more

Conditions: Cancer
Interventions: 5-FU, Atezolizumab, Bevacizumab, Carboplatin, Leucovorin, Nab-paclitaxel, Oxaliplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 11
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Soft Tissue Sarcoma
Interventions: Olaratumab, Gemcitabine, Docetaxel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 16 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 21
States / cities: Santa Monica, California • Aurora, Colorado • Jacksonville, Florida + 17 more

Conditions: Locally Advanced Head and Neck Carcinoma
Interventions: Dietary Supplement, Quality-of-Life Assessment, Questionnaire Administration; Dietary Supplement · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: VDC2008, Cyclophosphamide; Biological · Drug
Lead sponsor: Bostwick Laboratories; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Ventura, California

Conditions: Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions: ST101, Temozolomide, Radiation; Drug · Radiation
Lead sponsor: Sapience Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more

Conditions: Adenocarcinoma, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions: MiCK Assay; Procedure
Lead sponsor: Pierian Biosciences; Industry
Eligibility: Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Melanoma
Interventions: GSK1120212, Chemotherapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 13
States / cities: Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more

Search by objective public record fields.

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Study of IOV-5001 in Adults With Advanced Solid Tumors

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy

Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma